tradmap

ENGN Earnings enGene Therapeutics Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
$0 $76 $151 2022 2023 2024 2025
EPS
Net income (annual)
-$117M -$59M $0 2022 2023 2024 2025
Net income
Return on equity (annual)
-138% -53% 32% 0% 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$2 $15 $31 $0 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26
EPS
Net income (quarterly)
-$82M -$41M $0 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
Net income
Return on equity (quarterly)
-114% -57% 0% Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
ROE

Reported EPS history

1–16 of 16
Q3 20262026-07-31-1.342026-09-0810-Q
Q2 20262026-04-30-0.882026-06-1510-Q
Q1 20262026-01-310.442026-03-0910-Q
FY 20252025-10-312.292025-12-2210-K
Q3 20262025-07-31-1.562026-09-0810-Q
Q2 20262025-04-30-0.992026-06-1510-Q
Q1 20262025-01-310.482026-03-0910-Q
FY 20252024-10-311.462025-12-2210-K
Q3 20252024-07-311.122025-09-1110-Q
Q2 20252024-04-300.822025-06-1210-Q
Q1 20252024-01-310.462025-03-1010-Q
FY 20242023-10-31151.222024-12-1910-K
Q3 20242023-07-3130.772024-09-1010-Q
Q2 20242023-04-3022.192024-06-1410-Q
Q1 20242023-01-3113.292024-03-1110-Q
FY 20232022-10-3144.302024-01-2910-K

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.